The prospective randomized, placebo-controlled phase III CALGB 10603/RATIFY trial (NCT00651261) investigated the therapeutic benefit of midostaurin as a multi-targeted kinase inhibitor in combination with standard chemotherapy with cytarabine and daunorubicin in patients with newly diagnosed FLT3-mutated AML [44]. This evidence concerns the gene FLT3 and acute myeloid leukemia.